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ABSTRACT
Background: Recently, some common foods in daily life, especially lactic acid bacteria, have been found to
have anti-allergic effects. We previously isolated a halophilic lactic acid bacterium, Tetragenococcus halophi-
lus Th221, from soy sauce moromi, a mixture of koji and salt solution, and showed that it possesses an immu-
nomodulatory activity that promotes T helper type 1 immunity.
Methods: To evaluate the anti-allergic effects of Th221, we performed a randomized, double-blind, placebo-
controlled study in 45 subjects with perennial allergic rhinitis (PAR) treated by oral administration of Th221
(high dose, 60 mgday, 15 subjects; low dose, 20.4 mgday, 15 subjects) or a placebo (15 subjects) for 8
weeks.
Results: There were no significant differences among the groups that ingested Th221 and the placebo group
regarding the disease severities, total nasal symptom scores and total nasal sign scores examined by physi-
cians. However, the disease severity examined by physicians significantly improved in the high-dose group at
the end of the trial compared with the beginning (p < 0.05). The total score for nasal symptoms of subjects who
received a high dose of Th221 also showed a significant improvement at the end of the trial compared with the
beginning (p < 0.01). According to the subjects’ diaries, significant improvements in sneezing and rhinorrhea
were observed during some periods in the high-dose group. The change in serum total immunoglobulin E im-
proved significantly at the end of the trial compared with the beginning in this group (p < 0.05). The safety of
Th221 treatment was confirmed by laboratory tests and inspection of the general condition of each subject.
Conclusions: Th221 can be expected to safely improve the symptoms of PAR.
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INTRODUCTION
Allergic rhinitis is a symptomatic disorder of the nose
induced by immunoglobulin E (IgE)-mediated inflam-
mation of the membranes lining the nose after aller-
gen exposure,1 first defined in 1929.2 The three cardi-
nal symptoms of nasal reactions occurring in allergy
are sneezing, nasal obstruction and mucous dis-
charge. Recently, the incidences of both perennial al-
lergic rhinitis (PAR) and seasonal allergic rhinitis
have been increasing worldwide,1,3-6 leading to dra-
matic escalations in direct and indirect treatment
costs.
PAR is mainly caused by house dust and mites, and
its prevalence has reached 18.7% in the Japanese
population, which is higher than that of cedar pollino-
sis (16.2%).7 The therapeutic strategy for PAR usually
involves removal and avoidance of antigens by envi-
ronmental maintenance and pharmacotherapy. Inhibi-
tors of chemical mediators, anti-histamines and topi-
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Table 1 Characteristics of the patients enroled in the 
study
PlaceboLow doseHigh dose
151515n
36.5±2.836.7±1.233.8±2.0Age (mean±SE)
Sex
 4 9 7Male
11 6 8Female
Disease severity
 2 2 2Mild
131311Moderate
 0 0 2Severe
cal steroids are widely used, but their potential side
effects after long-term application are causes for con-
cern.
Recently, some common foods in daily life have
been found to have anti-allergic effects. There is
growing interest in this prospect, especially with re-
gard to lactic acid bacteria (LAB).8-11 We previously
isolated a halophilic LAB, Tetragenococcus halophilus
Th221, from soy sauce moromi, and showed that it
possesses an immunomodulatory activity that pro-
motes T helper type 1 (Th1) immunity.12 Specifically,
we found that Th1-dependent contact sensitivity was
augmented, while Th2 immunity evaluated by
allergen-specific IgE production was suppressed, fol-
lowing oral ingestion of Th221 in an in vivo mouse
study. Based on these findings, we investigated the
anti-allergic effects of Th221 in a randomized, double-
blind, placebo-controlled clinical trial in subjects with
PAR in the present study.
METHODS
SAMPLE PREPARATION
T. halophilus Th221 was heat-killed by incubation at
90℃ for 15 minutes. Three kinds of tablets weighing
200 mg were prepared as follows: placebo tablets con-
taining no Th221; low-dose tablets containing 3.4 mg
of Th221 per tablet; and high-dose tablets containing
10 mg of Th221 per tablet.
SUBJECTS
Forty-five PAR subjects (20 males, 25 female; age
range: 16―60 years) were enrolled in this clinical
study. The eligibility criteria for PAR were confirma-
tion of positive results in at least 2 of the following 3
tests according to the Guidelines for the Manage-
ment of Allergic Rhinitis in Japan (2002)13: (1) aller-
gen skin test or detection of serum allergen-specific
IgE against house dust or mites; (2) nasal provoca-
tion test; and (3) eosinophil count in nasal discharge.
The exclusion criteria were as follows: (a) combi-
nation with other nasal diseases; (b) sensitization to
other allergens that may influence the study; (c) com-
plication by systematic diseases; (d) simultaneous at-
tendance of another clinical trial; (e) pregnancy or
lactation; (f) poor health condition when consuming
soy sauce or LAB; and (g) inappropriate cases for the
trial as defined by physicians.
The present study followed the tenets of the Decla-
ration of Helsinki. In addition, written informed con-
sent was obtained from all subjects prior to participa-
tion in the study.
The detailed characteristics of the study subjects
are shown in Table 1. Each subject had a history of
PAR of more than 3 years. Among the 45 subjects
with PAR, 6 cases (13.3%) were diagnosed as mild, 37
cases (82.2%) as moderate and 2 cases (4.4%) as se-
vere according to the scores of the 3 main nasal
symptoms (sneezing, rhinorrhea and nasal obstruc-
tion) on the basis of the guidelines.
STUDY DESIGN
A randomized, double-blind, placebo-controlled trial
was performed at the following 3 institutions: Japa-
nese Red Cross Society Wakayama Medical Centre
(Wakayama); Dake ENT Clinic (Wakayama); and
Okuno ENT Clinic (Izumisano, Osaka). The trial was
performed between October 2005 and December
2005 in order to avoid any influence of the Japanese
cedar pollen season. The study was conducted at
TTC Co. Ltd. and approved by the Ethics Committee
of the Shinjuku Oiwake Clinic (Shinjuku, Tokyo).
METHODS
The subjects were randomly divided into 3 groups.
The first group received 6 placebo tablets per day
(placebo group; n = 15), the second group received 6
low-dose tablets containing 3.4 mg of Th221 per day
(low-dose group; total dose: 20.4 mgday; n = 15) and
the third group received 6 high-dose tablets contain-
ing 10 mg of Th221 per day (high-dose group; total
dose: 60 mgday; n = 15). Each subject received 2
tablets t.i.d. for a course of 8 weeks. After the admini-
stration was completed, there was a follow-up period
of 1 week, totaling a duration of 9 weeks. The clinical
characteristics of the subjects in the 3 groups are
shown in Table 1. There were no significant differ-
ences among the characteristics of the subjects.
During the study period, each subject visited a doc-
tor 3 times: at the beginning of the trial, during the
trial (week 4), and at the end of the trial (week 8).
Subjects were asked to record sneezing, rhinorrhea,
nasal obstruction and quality of life (QOL) on a daily
basis. A questionnaire was conducted regarding the
QOL in their daily lives and responses were evaluated
using a 5 grade system based on the guidelines (Ta-
ble 2).
The primary endpoints set before the beginning of
the study were disease severity, nasal symptoms
(sneezing, rhinorrhea and nasal obstruction) severi-
ties, QOL, nasal signs (mucosal swelling, mucosal
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Table 2 QOL questionnaire sheet
4＋ : Cannot work, study or complete houseworkEveningAfternoonMorning
3＋ : Interference with work, study or housework
＋4＋－
2＋ : Between 3＋ and ＋
＋ 　 :Litle interference with daily life
－ 　 :No problems
color, discharge volume and discharge character)
and allergic parameters (serum total IgE, serum
allergen-specific IgE, eosinophil count in nasal dis-
charge and neutrophil count in nasal discharge).
Disease severities, nasal symptoms (sneezing, rhi-
norrhea and nasal obstruction) severities and QOL
were scored by doctors using the subjects’ diaries.
Each subject’s nasal signs (mucosal swelling, mu-
cosal color, discharge volume and discharge fea-
tures) were also scored by doctors based on the
guidelines.
Total nasal symptom scores and total nasal sign
scores were obtained by adding symptom scores
(sneezing, rhinorrhea and nasal obstruction) and
sign scores (mucosal swelling, mucosal color, dis-
charge volume and discharge character), respec-
tively.
Medication scores were recorded according to
drug characteristics using the following guidelines:
second-generation antihistamines, mast cell stabiliz-
ers, vasoconstrictors and mast cell-stabilizing eye
drops, 1 point each; topical ocular and nasal steroids,
2 points each. Any concurrent use of drugs that could
influence the evaluation of efficacy was prohibited.
When evaluating the subjects’ diaries, the number
of sneezes and rhinorrhea events recorded in the dia-
ries were added up weekly. Nasal obstruction and
QOL were also quantified and added up weekly.
Evaluations were made for 8 weeks plus a follow-up
period of 1 week, totaling a period of 9 weeks.
Peripheral blood and urine routine examinations
were performed for each subject after the 3 visits to
their physician. Serum total IgE, serum allergen-
specific IgE (house dust, Dermatophagoides ptero-
nyssinus), eosinophil count in nasal discharge, neutro-
phil count in nasal discharge and TARC (Th2
marker) were also measured.
STATISTICAL ANALYSIS
Data are expressed as means ± SE. Disease severities
evaluated by physicians and eosinophil counts in na-
sal discharge were evaluated within groups and be-
tween groups using one-sample and two-sample Wil-
coxon tests, respectively. Intragroup and intergroup
differences in nasal symptom scores, nasal sign
scores, total nasal symptom scores, total nasal sign
scores, diagnostic scores and rates of score changes
using the subjects’ diaries were evaluated using one-
sample and two-sample t-tests, respectively. Medica-
tion scores were recorded by drug characteristics
and evaluated using a two-sample Wilcoxon test. Dif-
ferences were considered to be significant at p < 0.05.
RESULTS
DISEASE SEVERITIES, TOTAL NASAL SYMP-
TOM SCORES AND TOTAL NASAL SIGN
SCORES
Disease severities found by physicians based on the
subjects’ diaries (sneezing, rhinorrhea and nasal ob-
struction) during the study are shown in Table 3. Al-
though no significant differences could be seen be-
tween any 2 groups, disease severity significantly im-
proved in the high-dose group at the end of the trial
compared with the beginning (p < 0.05). No signifi-
cant changes were found during the trial in the pla-
cebo and low-dose groups. There were no significant
differences between any 2 groups regarding nasal
symptom (sneezing, rhinorrhea and nasal obstruc-
tion) severities, QOL and nasal sign scores (mucosal
swelling, mucosal color, discharge volume and dis-
charge character).
The total nasal symptom scores during the study
are shown in Table 4. A comparison of the high-dose
and placebo groups revealed a tendency toward im-
provement in the high-dose group (p = 0.091), and
the score significantly improved in the high-dose
group at the end of the trial compared with the begin-
ning (p < 0.01). Regarding the total nasal sign score,
there were no significant differences among the
groups that ingested Th221 and the placebo group,
and significant improvements were observed in all 3
groups at the end of the trial compared with the be-
ginning (p < 0.01).
The medication scores recorded by drug character-
istics were evaluated using a two-sample Wilcoxon
test, and no significant differences were observed
among the groups.
EVALUATION OF THE SUBJECTS’ DIARIES
Because 1 subject in each of the low-dose and high-
dose groups forgot to record their details at the be-
ginning of the trial, they were excluded from the
analysis. In addition, 2 subjects in the placebo group
and 3 subjects in the high-dose group whose sneez-
ing or rhinorrhea increased by more than 100 num-
ber of times, compared with the beginning of the
trial, were excluded. Therefore, an analysis was car-
ried out for 13 subjects in the placebo group, 14 sub-
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Table 3 Disease severities examined by physicians (presented as numbers of subjects)
Intergroup
p value
Intragroup
p value
No
symptomsMildModerateSevere
Very
severe
Time 
(weeks)Group
256200
Placebo 0.755176104
0.245276008
176100
Low dose 0.6540.4010114004
0.6840.5951102208
436200
High dose 0.6540.401293104
0.453 0.029＊581108
The disease severities were examined by physicians using the subjects’diaries (sneezing, rhinorhea and nasal obstruction) during the 
study. ＊p ＜0.05 compared to the beginning of the trial. 
Table 4 Total nasal symptom scores (combination of 
sneezing, rhinorhea and nasal obstruction) in perennial al
lergic rhinitis subjects during the trial
Time (weeks)
Group
840
2.673.073.13Placebo
3.072.873.20Low dose
1.67＊＊2.932.73High dose
A placebo, low dose of Th221 (20 mg/day) or high dose of 
Th221 (60 mg/day) was administered for 8 weeks. ＊＊p＜0.01 
compared to the beginning of the trial.
jects in the low-dose group and 11 subjects in the
high-dose group.
The mean rates of changes from the baseline
scores for sneezing during the study are shown in Ta-
ble 5. There were no significant changes between any
2 groups. However, the rate of change in sneezing in
the high-dose group showed a significant improve-
ment during the first week (p < 0.05) and second
week (p < 0.05), compared with the beginning of the
trial. No significant changes were observed in the pla-
cebo group or low-dose group compared with the be-
ginning of the trial.
The mean rates of change from the baseline scores
for rhinorrhea during the study are shown in Table 6.
In comparison with the placebo group, the rate of
change in rhinorrhea in the high-dose group signifi-
cantly improved during the first (p < 0.05) and second
week (p < 0.05). A significant improvement could also
be found in the low-dose group during the first week
(p < 0.05) in comparison with the placebo group. The
rate of change in rhinorrhea in the high-dose group
began to improve during the second week (p = 0.062)
compared with the beginning of the trial. No signifi-
cant changes could be observed in the placebo group
or low-dose group, compared with the beginning of
the trial.
No significant changes were found between any 2
groups regarding the rate of change in nasal obstruc-
tion and QOL. The rate of change in nasal obstruction
in the high-dose group showed significant improve-
ment by the fifth week (p < 0.05) compared with the
beginning of the trial (data not shown). Significant
changes were also observed in the placebo group at
the third week (p < 0.05) and fourth week (p < 0.05)
compared with the beginning of the trial (data not
shown). No significant changes were found in the
low-dose group compared with the beginning of the
trial.
The rate of change in QOL in the low-dose group
improved significantly at the 7th week (p < 0.05) com-
pared with the beginning of the trial (unpublished
data). However, no significant changes were ob-
served in the placebo group or high-dose group com-
pared with the beginning of the trial.
ALLERGIC TESTS
Since there were no significant improvements in se-
rum allergen-specific IgE (house dust, D. pteronyssi-
nus) (Table 7), it can be said that the improvement in
symptoms induced by Th221 were not marked. In ad-
dition, no significant improvements were found in the
following allergic markers in PAR subjects: eosino-
phil count in nasal discharge (Table 7); neutrophil
count in nasal discharge; and TARC (Th2 marker). In
the high-dose group, however, a significant decrease
in the change in serum total IgE was observed at the
end of the trial (week 8; p < 0.05) compared with the
beginning (Fig. 1, Table 7).
SAFETY
No adverse effects were observed during the study.
Common colds and diarrhea were reported by some
subjects, however the degrees of symptoms were
slight and disappeared during the study, and may
have had no relationship with the trial.
Soy Sauce Bacterium Improves Allergy
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Table 5 Mean rates of change from the baseline scores for sneezing evaluated using the subjects’diaries
Time (weeks)
Group
9876543210
6.15－3.001.54－0.541.46－1.54－4.23－1.38－2.540.00Placebo
－2.64－0.860.215.140.711.790.573.646.930.00Low dose
5.82－2.64－6.452.64－8.09－7.91－3.55－8.09＊－6.91＊0.00High dose
The first day of administration (baseline) is indicated as 0 weeks. A placebo, low dose of Th221 (20 mg/day) or high dose of Th221 (60 
mg/day) was administered for 8 weeks. After the administration was completed, a folow-up period of 1 week was set up, giving a final 
time point of 9 weeks. ＊p＜0.05 compared with the baseline score in each group.
Table 6 Mean rates of change from the baseline scores for rhinorhea evaluated using the subjects’diaries
Time (weeks)
Group
9876543210
7.156.1515.238.463.54－1.54－0.084.54　5.31　0.00Placebo
3.143.712.935.364.501.07－0.934.36　－2.29＋0.00Low dose
10.093.00－2.091.55－4.00－3.64－0.64－5.36＋－4.18＋0.00High dose
The first day of administration (baseline) is indicated as 0 weeks. A placebo, low dose of Th221 (20 mg/day) or high dose of Th221 (60 
mg/day) was administered for 8 weeks. After the administration was completed, a folow-up period of 1 week was set up, giving a final 
time point of 9 weeks. ＋p＜0.05 compared to the placebo group.
Table 7 Efects of Th221 treatment on serum IgE and eosinophil counts of perennial alergic rhinitis subjects
Week 8Week 4Week 0Group
343±101372±117381±130PlaceboTotal IgE
(IU/ml)  358±　71  391±　86  377±　73 Low dose
1021±643 1021±643 1122±745 High dose
101.1±3.8  105.4±6.5  100.0PlaceboChange in total IgE
(%) 95.0±3.0 100.7±3.5  100.0Low dose
94.1±2.1＊100.9±2.6  100.0High dose
2.5±0.42.5±0.32.5±0.3PlaceboHouse dust-specific IgE
(Class) 2.7±0.32.7±0.32.7±0.3Low dose
3.1±0.33.1±0.33.1±0.3High dose
2.7±0.42.5±0.42.6±0.3PlaceboD. pteronyssinus-specific IgE
(Class) 2.7±0.32.7±0.32.7±0.3Low dose
3.1±0.43.0±0.43.0±0.4High dose
5.2±1.04.7±0.85.5±0.9PlaceboEosinophil count
(%) 4.9±0.84.2±0.54.7±0.8Low dose
5.3±0.84.7±0.75.1±0.8High dose
Each value represents the mean±SE.＊p＜0.05 compared to the beginning of the trial.
DISCUSSION
PAR attacks in all seasons and predominates in
younger children, rendering it harder to cure. Al-
though a variety of medicine for PAR have been de-
veloped and applied clinically, PAR subjects typically
need to use these drugs for the entire year with con-
sideration for side effects. In addition, there are only
a few kinds of medicine for PAR which are appropri-
ate for younger children.
With this in mind, it may be interesting to identify
foods with anti-allergic effects, as these could be ex-
pected to reduce dependence on drugs to some ex-
tent. One such promising food is LAB.8 Several clini-
cal trial reports have indicated that intake of LAB im-
proves the symptoms of some kinds of allergies.9-11
In the present study, we evaluated the anti-allergic
effects of the LAB T. halophilus Th221, which we pre-
viously isolated from soy sauce moromi.12 The clini-
cal findings by physicians improved significantly in
the high-dose group during the latter half of the trial.
Furthermore, during this period, the subjects’ diaries
revealed a decrease in the rates of change from the
baseline scores for sneezing at weeks 4, 5, 7 and 8
(Table 5) and rhinorrhea at weeks 4, 5 and 7 (Table
6) in the high-dose group, although the changes were
Nishimura I et al.
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Fig. 1 Rate of change in serum total IgE in the placebo 
group and high-dose group (60 mg of Th221 per day) before 
and after the trial. ＊ p＜0.05 compared with the beginning of 
the trial.
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not significant. These results are consistent with the
findings by physicians. According to the subjects’ dia-
ries, however, significant improvements were found
in earlier periods for both the rate of change from the
baseline scores for sneezing in the high-dose group,
and the rate of change for rhinorrhea in the high-
dose group compared with the placebo group, which
were inconsistent with the physicians’ findings.
Moreover, significant changes were found in the rate
of change for nasal obstruction in the placebo group
at the third and fourth weeks, compared with the be-
ginning of the trial. Therefore, the data from the sub-
jects’ diaries appear to be less consistent, and we con-
sider it highly likely that significant early improve-
ments included a placebo effect. In the present study,
the change in serum total IgE significantly improved
in the high-dose group at the end of the trial com-
pared with the beginning, which supports the im-
provement found in clinical findings.
It has often been proposed that one mechanism for
LAB-induced suppression of allergic responses is a
reduction in IgE due to improvement of the Th1Th2
balance.8,14 For example, a clinical trial report that
Enterococcus faecalis FK-23 improves the symptoms
of PAR mentions that one of its mechanisms may in-
volve improvement of the Th1Th2 balance.10 In that
trial, tuberculin responses were also measured, and a
significant inverse correlation was recognized be-
tween skin test diameters and symptoms. The
authors interpreted these findings as being due to en-
hancement of host Th1-type immune responses and
suppression of the overexpression of Th2-dominated
allergic responses.
Some LAB strains have been proven to improve the
Th1Th2 balance in vitro and in vivo. For example,
Lactobacillus paracasei KW3110, which was selected
to show both high IL-12-inducing activity and high IL-
4-suppressing activity, reduced antigen-specific IgE in
an ovalbumin (OVA)-sensitized mouse model by im-
proving the Th1Th2 balance.14 It was also reported
that increased Th1 cytokine levels and decreased Th2
cytokine levels were found in splenocytes from OVA-
sensitized mice that had ingested Lactobacillus casei
Shirota.15
T. halophilus strain Th221 used in the present
study was selected because it exhibited strong IL-12-
inducing activity on mouse peritoneal macrophages.12
A Th1-promoting activity was also manifested in an in
vivo mouse study, because Th1-dependent contact
sensitivity was augmented and Th2 immunity evalu-
ated by allergen-specific IgE production was sup-
pressed following oral ingestion of Th221. In the pre-
sent clinical study, the change in total IgE signifi-
cantly decreased, and this may be explained by im-
provement of the Th1Th2 balance due to the Th1-
promoting activity of Th221. However, the activity
does not seem to be sufficiently strong to induce a
significant decrease in serum allergen-specific IgE. In
many clinical trials testing the beneficial effects of
LAB or other foods, allergic symptoms have often im-
proved, but a significant reduction in serum IgE is
not commonly observed.9,11,16,17 Therefore, it is worth
noting that serum total IgE decreased due to Th221
in the present trial.
It has recently been reported that Lactobacillus aci-
dophilus L-92 can induce apoptosis of Th2 cells, in ad-
dition to enhancing Th1 responses.18 It will be inter-
esting to investigate whether Th221 also possesses
this activity. Furthermore, it has often been sug-
gested that regulatory T cells19 or Th17 cells20 are re-
lated to allergic responses, but only the Th1Th2 bal-
ance is usually taken into account. Therefore, we
need to search for further mechanisms with this in
mind.
Another possibility is that Th221 may have im-
proved allergic symptoms by improving the intestinal
microflora. The role for intestinal microflora, such as
several strains of LAB, in priming the immune sys-
tem during ontogeny to limit allergy has been
pointed out.21 Epidemiological studies have shown a
higher incidence of allergy expression in early child-
hood among children with low enteric LAB popula-
tions, supporting the notion that appropriate micro-
bial colonization of the gut can lower the risk of de-
Soy Sauce Bacterium Improves Allergy
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veloping an allergy.22,23 There is also clinical evi-
dence that appropriate gut-colonizing microbes can
control the development of atopy.24 In addition, there
is a report that administration of heat-killed LAB can
improve intestinal microflora in adults.25 Therefore,
Th221 may contribute to the improvement of allergic
symptoms via this mechanism.
The human gut is known to contain more than 1 kg
of intestinal microorganisms.26 It is extremely inter-
esting and surprising that such a small amount of
LAB, even if heat-killed, can lead to the improvement
of allergic symptoms. It is also important to clarify
which components of LAB provide beneficial effects.
Further studies and development are required to pro-
vide beneficial and evidence-based foods to improve
allergic symptoms.
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